Avalo Therapeutics announced positive Phase 2 results for Abdakibart (AVTX-009) in treating moderate to severe hidradenitis suppurativa (HS). The LOTUS trial met its primary endpoint with response rates over 42% at Week 16, the highest observed in trials of this size, showing significant improvement in key clinical measures. Abdakibart was well tolerated with a favorable safety profile, and Avalo plans to advance the drug into Phase 3 registrational trials. This progress highlights the potential of IL-1β inhibition as a new treatment option for HS patients.
The Schall Law Firm is investigating UP Fintech Holding Limited for possible securities law violations after a Reuters report revealed China's crackdown on illegal cross-border securities trading. The report accused UP Fintech's Tiger subsidiary of o...
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
Guardian Exploration Inc. completed a private placement, raising $1.72 million by issuing 6.89 million units at $0.25 each. Each unit includes one flow-through common share and one warrant exercisable at $0.40 for two years. The funds will support ex...
Talk of a Tesla-SpaceX merger is intensifying as Elon Musk moves closer to taking SpaceX public. The two companies already share engineering talent and collaborate on energy, computing, and infrastructure challenges. The potential deal is largely dri...
The 2026 China (Jinhua Mountain) International Camping Congress was held from May 16-17 in Zhejiang Province, focusing on integrating culture, sports, tourism, and industry to promote high-quality development of camping tourism and leisure. The event...
